Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine versus conventional chemotherapy as consolidation in elderly AML in first complete remission
2012-000981-40Phase 2Terminated
- Sponsor
- Swedish AML Group
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Swedish AML Group. Primary endpoint: Leukemia-free survival at 12 months. Started Sep 2012; status: terminated.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-000981-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000981-40.